Thank you! Yeah, it’s taken a lot of patience and ups and downs to reach this kind of amazing level as you are describing.
E2E was bought 2.5 years ago, in December 2023, at 60 level, so it’s almost 10x, and my first one at that, targeting much more. But then it’s only retracing back to the level it already reached in November 2024, drawing a nice technical cup or roller-coaster chart. It’s my second oldest holding after KPI green, which is only about 5x in exactly 4 years.
Sky gold is kind of substitute for shunning precious metals, this being bought for 270 in September 2024, in almost 2 years gone almost 3x, pretty long wait here too, but thankfully it stayed quite level most of the time, giving overall stability for quite a while.
Freshara is also almost 3x but took only about half a year, a nice booster effect, with much more to come.
Portfolio hardly grew in past couple of years compared to the post covid hockey stick style of growth, but overall quite satisfied with performance.
Yes, the magic as you say is in the sizing. Better opportunity lies ahead now in the cycle.
I appreciate what you’re talking about and the incredible patience you’ve shown, because I was also holding both these shares at good prices but I couldn’t hold on to them when they fell due to lack of patience and vision.
It’s a pleasure to watch your portfolio and learn from it. Thanks a lot for sharing these valuable insights.
Sold off KPI green and bought V-marc instead, held it for 4 years exactly, longest time ever.
KPI Green was getting buried under capex and debt, and doubtful overseas expansion plan.
Vmarc promotor was banned by sebi for circular trading, trying to manipulate price after ipo, but may be let’s forget it since some 4 years old news. They sell usual electric cables, strong market, now moving from government orders to retailers. Just started voluntary quarterly reporting and planning a fund raise of ~800 crore.
Sold shilchar, it is export dependent, looks like shipping and demand both got hit. Held it for little under 3 years.
Bought Venus remedies, it is bit like Wockhardt, both ideas borrowed from @phreakv6, they experienced insolvency like conditions few years ago, but have restructured to come back stronger. Export focused pharma business should show steady growth.
Disclosure: None of the above is investment advice, I am not a registered financial advisor, please do your own due diligence before investing
Venus molecules still in phase1 trail, balance sheet not so strong to support drug development, failure rates are very high in phase1 & phase 2, phase 3 is a killer with success rate for a noval drug of just 3%. Betting on new drugs is just like a lottery. Wockhardt had to sell his hospital business and some other businesses to fund molecule research, 20 years program.
I didn’t mean to compare directly with Wockhardt, the valuation difference speaks for itself. My entry @1567 was bit technical too, strong support at 50dma for long time. Got lucky here, into good profits!
My guess is Venus will not be adventurous with new drug discovery, given their past. I am totally discounting that aspect, for good or bad. If they just continue to incrementally improve their sales biz, it’s enough to justify a punt on the company. It’s the gist of the same thing I think Bharani was pointing out.
I have 24 stocks in my PF, this is weighted exactly in the middle, no great stakes either ways.
